Alpa Laboratories Ltd
Incorporated in 1988, Alpa Laboratories Ltd manufactures and sells Drugs and Chemicals[1]
- Market Cap ₹ 205 Cr.
- Current Price ₹ 97.2
- High / Low ₹ 115 / 55.0
- Stock P/E 11.4
- Book Value ₹ 72.9
- Dividend Yield 0.00 %
- ROCE 8.99 %
- ROE 7.26 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company is expected to give good quarter
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of 8.57% over past five years.
- Company has a low return on equity of 6.09% over last 3 years.
- Earnings include an other income of Rs.10.2 Cr.
- Company has high debtors of 184 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
55 | 56 | 56 | 57 | 53 | 63 | 62 | 77 | 85 | 97 | 112 | 93 | 114 | |
53 | 53 | 51 | 54 | 47 | 56 | 57 | 76 | 79 | 90 | 101 | 85 | 100 | |
Operating Profit | 3 | 3 | 6 | 3 | 7 | 7 | 4 | 1 | 6 | 8 | 11 | 8 | 14 |
OPM % | 5% | 5% | 10% | 6% | 13% | 11% | 7% | 2% | 7% | 8% | 10% | 9% | 12% |
1 | 0 | 1 | 2 | 6 | 4 | 5 | 5 | 0 | 4 | 11 | 9 | 10 | |
Interest | 1 | 2 | 2 | 2 | 1 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
Depreciation | 1 | 5 | 9 | 6 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 2 |
Profit before tax | 1 | -3 | -5 | -3 | 11 | 9 | 7 | 5 | 5 | 11 | 20 | 16 | 22 |
Tax % | 37% | -36% | -4% | 48% | 27% | 34% | 27% | 36% | 20% | 33% | 28% | 21% | |
1 | -4 | -5 | -1 | 8 | 6 | 5 | 3 | 4 | 7 | 14 | 13 | 18 | |
EPS in Rs | 0.25 | -2.08 | -2.45 | -0.67 | 3.68 | 2.85 | 2.27 | 1.40 | 1.94 | 3.45 | 6.72 | 6.00 | 8.52 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 5% |
5 Years: | 9% |
3 Years: | 3% |
TTM: | 29% |
Compounded Profit Growth | |
---|---|
10 Years: | 16% |
5 Years: | 15% |
3 Years: | 23% |
TTM: | 312% |
Stock Price CAGR | |
---|---|
10 Years: | 27% |
5 Years: | 31% |
3 Years: | 15% |
1 Year: | 59% |
Return on Equity | |
---|---|
10 Years: | 4% |
5 Years: | 5% |
3 Years: | 6% |
Last Year: | 7% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 |
Reserves | 77 | 72 | 67 | 66 | 73 | 77 | 82 | 85 | 89 | 96 | 111 | 123 | 132 |
12 | 17 | 23 | 29 | 24 | 11 | 6 | 2 | 0 | 0 | 6 | 3 | 2 | |
20 | 14 | 15 | 13 | 27 | 20 | 17 | 21 | 21 | 33 | 28 | 30 | 39 | |
Total Liabilities | 130 | 125 | 127 | 128 | 145 | 129 | 127 | 129 | 131 | 150 | 165 | 178 | 194 |
9 | 80 | 73 | 5 | 5 | 5 | 6 | 6 | 6 | 7 | 9 | 7 | 7 | |
CWIP | 59 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 |
Investments | 0 | 0 | 0 | 10 | 22 | 23 | 41 | 59 | 68 | 62 | 86 | 90 | 117 |
62 | 45 | 54 | 113 | 118 | 100 | 79 | 64 | 56 | 80 | 70 | 81 | 70 | |
Total Assets | 130 | 125 | 127 | 128 | 145 | 129 | 127 | 129 | 131 | 150 | 165 | 178 | 194 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-1 | 3 | 8 | -2 | -25 | -8 | -7 | -1 | 18 | -1 | 2 | 9 | |
-1 | -4 | -2 | 37 | -7 | 1 | -16 | -15 | -11 | 6 | -16 | 2 | |
1 | 2 | 4 | 7 | -6 | -2 | 4 | -5 | -1 | -0 | 5 | -3 | |
Net Cash Flow | -1 | 0 | 10 | 42 | -37 | -9 | -19 | -20 | 5 | 4 | -8 | 7 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 142 | 127 | 130 | 156 | 234 | 169 | 151 | 141 | 105 | 133 | 124 | 184 |
Inventory Days | 142 | 132 | 148 | 76 | 196 | 131 | 140 | 105 | 90 | 102 | 81 | 84 |
Days Payable | 142 | 85 | 121 | 91 | 244 | 140 | 130 | 99 | 98 | 152 | 78 | 100 |
Cash Conversion Cycle | 142 | 174 | 157 | 141 | 187 | 160 | 161 | 148 | 97 | 83 | 127 | 168 |
Working Capital Days | 265 | 187 | 169 | 178 | 390 | 256 | 234 | 194 | 121 | 137 | 136 | 155 |
ROCE % | 2% | -1% | -3% | 0% | 10% | 11% | 7% | 4% | 7% | 7% | 9% | 9% |
Documents
Announcements
-
Certificate Under Regulation 40(9) Of The (LODR) Regulations, 2015.
15 Apr - Certificate under Regulation 40(9) of the (LODR) Regulations, 2015 for the financial year ended 31st March, 2024.
- Compliance Certificate Submitted For The Period Ended March, 2024. 13 Apr
- Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 11 Apr
- Shareholder Meeting / Postal Ballot-Outcome of AGM 10 Apr
- Closure of Trading Window 1 Apr
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2011
from nse
-
Financial Year 2010
from bse
Business Overview:[1]
ALL is a WHO-GMP and ISO 9001:2000 certified company. It manufactures a wide range of Pharmaceutical Finished Dosage Forms under its own brand and for other Indian and multinational companies. The product range includes a wide variety of ethical, generic, and over-the-counter (OTC) drugs in various Finished Dosage Forms for both human and veterinary use